News >

Expert Underscores Importance of AE Management in GU Cancers

Caroline Seymour
Published: Wednesday, May 09, 2018

Xiao X. Wei, MD

Xiao X. Wei, MD
Although they tend to be less common, adverse event (AE) management is still imperative with immunotherapies and requires a multidisciplinary approach, says Xiao X. Wei, MD, MAS.

“There are no prospective data per se or high-level evidence on how to best treat side effects, [and though] the ASCO, NCCN, and ESMO guidelines have given us more tools to work with…every patient is different, and we have to employ our clinical judgement,” says Wei.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication